• slide_1_800x340
  • slide_2_800x340
  • slide_3_800x340

Benovus Bio is a privately held biotechnology company dedicated to improving the treatment outcomes and quality of life for cancer patients via the research, development, and commercialization of innovative immunotherapeutic products.

Benovus Bio has received authorization from the Food and Drug Administration (FDA) to proceed with a Phase I Clinical Trial utilizing Benovus' proprietary multipeptide immunotherapy in patients with Acute Myeloid Leukemia (AML), Multiple Myeloma (MM), and Myelodysplastic Syndrome (MDS). For more information, click here.